EKSO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ekso Bionics Holdings Inc (EKSO) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown slight revenue growth and an improved gross margin, the significant drop in net income and EPS, combined with weak technical indicators and lack of positive trading signals, suggests a cautious approach. The absence of recent news, congress trading data, and analyst ratings further limits visibility on potential catalysts.
The technical indicators are mixed. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 44.388, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 10.9, with key support at 9.158 and resistance at 12.642. Overall, the technical setup is not strongly supportive of a buy.
Revenue increased by 2.37% YoY in Q3 2025, and gross margin improved by 12.71% YoY to 60.3%.
Net income dropped by 31.42% YoY, and EPS fell by 64.71% YoY. The MACD is bearish, and there is no significant hedge fund or insider trading activity. No recent news or congress trading data is available.
In Q3 2025, revenue increased to $4.227 million (+2.37% YoY), gross margin improved to 60.3% (+12.71% YoY), but net income dropped to -$1.421 million (-31.42% YoY), and EPS fell to -0.54 (-64.71% YoY).
No data available for analyst ratings or price target changes.
